Modified Rodnan Skin Score and its Association with Extent of Lung Damage in Systemic Sclerosis Patients
Keywords:ILD, FVC, HRCT, MRSS, Systemic Sclerosis.
AbstractBack Ground: Systemic sclerosis is a progressive, multi-organ autoimmune connective tissue disorder associated with widespread skin and internal organ fibrosis. Skin thickness correlates with organ invol-vement. Modified Rodnan skin score (MRSS) is a reliable way to measure skin thickness for assessing severity and outcome of the disease. Objective: To evaluate association of MRSS with severity of lung disease in systemic sclerosis. Methods: A cross-sectional study was conducted at Department of Rheumatology and Immunology Shaikh Zayed Hospital, Lahore from January 2020 - June 2020. After approval from Institutional Review Board 35 patients fulfilling the inclusion criteria were included through non-probability/convenience sampling. After a detailed history MRSS was measured using standard method. Pulmonary manifestations and internal organ assessment were done performing Force Vital Capacity (FVC), X-ray chest, echocardiography and High-Resolution CT scan chest (HRCT). Data was analyzed in SPSS ver: 25.0. Pearson correlation was calculated for MRSS and FVC. MRSS was cross tabulated with interstitial lung disease (ILD) and pulmonary hypertension. Chi-square test was used for statistical significance at p < 0.05. Results: The mean age was 43.17 years + 11.67. 85.7% were females. 88.6% were married, with no family history of disease and smoking. Mean FVC was 67.428 + 16.077. MRSS range was 4-45 with a mean MRSS score of 17.800 + 11.208. Pearson product moment correlation revealed negative correlation of MRSS with FVC, r = -0.428 P = 0.010. MRSS was cross tabulated with ILD and showed statistically significant result with P = 0.006. Pulmonary hypertension was present in 42.9% of patients. Of these 53.3% had mild, 33.3% and 13.3% had moderate and severe thickening on MRSS respectively. (p = 0.590). Conclusion: MRSS is a reliable tool for assessing and evaluating severity of lung disease in systemic sclerosis.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments email@example.com